The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the “Company”) was held on June 16, 2021 by postal voting whereby the shareholders resolved on the following matters.
Annual report and results
The annual general meeting adopted the income statement and the balance sheet for the financial year 2019/2020 and resolved, in accordance with the board of directors’ proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are to be paid.
Discharge from liability
The general meeting resolved that the former board director Chunde Li was not discharged from liability for the financial year 2019/2020, since shareholders representing more than one tenth of the total number of shares in the company voted against discharge from liability regarding him. The general meeting granted the managing director as well as the remaining board of directors discharge from liability for the management of the Company’s business for the financial year 2019/2020.
Remuneration to the board of directors and the auditor
The annual general meeting resolved that the chairman shall receive remuneration with SEK 150,000 and that every other board member shall receive remuneration with SEK 75,000, unless the member in question is not prevented from receiving such remuneration due to the applicable guidelines of the member’s employer.
The annual general meeting resolved that the auditor shall receive remuneration according to approved invoice.
Election of board of directors and auditor
The annual general meeting resolved that the board of directors shall consist of four (4) directors without any deputy directors.
The general meeting resolved, for the time until the end of the next annual general meeting, to re-elect Anders Lundberg, Michael Häggman, Karlheinz Schmelig and Håkan Englund as members of the board of directors. Anders Lundberg was elected as the chairman of the board of directors.
It was resolved to re-elect Grant Thornton Sweden AB as auditor, with Anders Meyer as chief auditor, for the time until the end of the next annual general meeting.
Nomination committee for the annual general meeting 2022
The annual general meeting resolved that the Company, in advance of the annual general meeting in 2022, shall establish a nomination committee. It was resolved that the members of the nomination committee shall be appointed by instruction from the chairman of the board of directors to the three largest shareholders in the Company on 30 September 2021 to appoint a representative each that, together with the chairman of the board of directors, shall constitute the nomination committee.
Authorization to the board of directors to resolve on new issues
The annual general meeting authorized the board of directors to, one or several occasions for the time until the next annual general meeting, increase the Company’s share capital with with an amount that corresponds to twenty (20) percent of the Company’s registered share capital at the time of the first utilisation of the authorisation. The board of directors shall be entitled to resolve on issues of shares, warrants and/or convertible instruments with or without deviation from the shareholders’ pre-emption rights and/or by an issue in kind or by way of set-off. An issue in accordance with the authorization shall be made at fair market value.
The resolution was supported by shareholders holding more than two thirds of the votes cast and the shares represented at the general meeting.
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 16-06-2021 16:15 CET.